{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:06:44Z","timestamp":1785409604226,"version":"3.56.0"},"reference-count":32,"publisher":"Scientific Archives","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.scientificarchives.com\/about-us"}],"funder":[{"award":["R01 CA098761"],"award-info":[{"award-number":["R01 CA098761"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["U01 CA154967"],"award-info":[{"award-number":["U01 CA154967"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Immunol"],"DOI":"10.33696\/cancerimmunol.8.119","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:30:22Z","timestamp":1776666622000},"page":"13","source":"Crossref","is-referenced-by-count":0,"title":["Predicting Durable Anti-tumor Immune Responses after Cancer Vaccines"],"prefix":"10.33696","volume":"8","author":[{"given":"John B.","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L.","family":"Disis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18993","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tPail O, Lin MJ, Anagnostou T, Brown BD, Brody JD. Cancer vaccines and the future of immunotherapy. Lancet. 2025 Jul 12;406(10499):189\u2013202.","DOI":"10.1016\/S0140-6736(25)00553-7"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tAhmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996 Apr 5;272(5258):54\u201360.","DOI":"10.1126\/science.272.5258.54"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tPalucka AK, Coussens LM. The Basis of Oncoimmunology. Cell. 2016 Mar 10;164(6):1233\u201347.","DOI":"10.1016\/j.cell.2016.01.049"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tRomero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, et al. The Human Vaccines Project: A roadmap for cancer vaccine development. Sci Transl Med. 2016 Apr 13;8(334):334ps9.","DOI":"10.1126\/scitranslmed.aaf0685"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tMittra S, Harding SM, Kaech SM. Memory T Cells in the Immunoprevention of Cancer: A Switch from Therapeutic to Prophylactic Approaches. J Immunol. 2023 Sep 15;211(6):907\u201316.","DOI":"10.4049\/jimmunol.2300049"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tSlingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, et al. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res. 2013 Aug 1;19(15):4228\u201338.","DOI":"10.1158\/1078-0432.CCR-13-0002"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tMcNeel DG, Eickhoff JC, Wargowski E, Zahm C, Staab MJ, Straus J, et al. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2018 May 22;9(39):25586\u201396.","DOI":"10.18632\/oncotarget.25387"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tMizukoshi E, Nakagawa H, Tamai T, Kitahara M, Fushimi K, Nio K, et al. Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. Nat Commun. 2022 Jun 3;13(1):3123.","DOI":"10.1038\/s41467-022-30861-z"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tAruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, et al. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. Clin Cancer Res. 2013 Apr 15;19(8):2224\u201331.","DOI":"10.1158\/1078-0432.CCR-12-3592"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tOdunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5797\u2013802.","DOI":"10.1073\/pnas.1117208109"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tvan Baren N, Bonnet MC, Dr\u00e9no B, Khammari A, Dorval T, Piperno-Neumann S, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol. 2005 Dec 10;23(35):9008\u201321.","DOI":"10.1200\/JCO.2005.08.375"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tKirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+\/-granulocyte-monocyte colony-stimulating factor and\/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009 Feb 15;15(4):1443\u201351.","DOI":"10.1158\/1078-0432.CCR-08-1231"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tDisis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2\/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009 Oct 1;27(28):4685\u201392.","DOI":"10.1200\/JCO.2008.20.6789"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tGulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010 May;59(5):663\u201374.","DOI":"10.1007\/s00262-009-0782-8"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tMoon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, Kedl RM, et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity. 2007 Aug;27(2):203\u201313.","DOI":"10.1016\/j.immuni.2007.07.007"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tFraser KA, Schenkel JM, Jameson SC, Vezys V, Masopust D. Preexisting high frequencies of memory CD8+ T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting. Immunity. 2013 Jul 25;39(1):171\u201383.","DOI":"10.1016\/j.immuni.2013.07.003"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tMartin MD, Wirth TC, Lauer P, Harty JT, Badovinac VP. The impact of pre-existing memory on differentiation of newly recruited naive CD8 T cells. J Immunol. 2011 Sep 15;187(6):2923-31.","DOI":"10.4049\/jimmunol.1100698"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tJoshi NS, Cui W, Dominguez CX, Chen JH, Hand TW, Kaech SM. Increased numbers of preexisting memory CD8 T cells and decreased T-bet expression can restrain terminal differentiation of secondary effector and memory CD8 T cells. J Immunol. 2011 Oct 15;187(8):4068\u201376.","DOI":"10.4049\/jimmunol.1002145"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tRizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med. 2009 Apr 13;206(4):849\u201366.","DOI":"10.1084\/jem.20081382"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tMalandro N, Budhu S, Kuhn NF, Liu C, Murphy JT, Cortez C, et al. Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. Immunity. 2016 Jan 19;44(1):179\u2013193.","DOI":"10.1016\/j.immuni.2015.12.018"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tLiao JB, Dai JY, Reichow JL, Lim JB, Hitchcock-Bernhardt KM, Stanton SE, et al. Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response. J Immunother Cancer. 2024 Nov 9;12(11):e010251.","DOI":"10.1136\/jitc-2024-010251"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tSaxena M, Van TTH, Baird FJ, Coloe PJ, Smooker PM. Pre-existing immunity against vaccine vectors--friend or foe? Microbiology (Reading). 2013 Jan;159(Pt 1):1\u201311.","DOI":"10.1099\/mic.0.049601-0"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tPine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, et al. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5\/HIV-1 vaccine candidate in humans. PLoS One. 2011 Apr 13;6(4):e18526.","DOI":"10.1371\/journal.pone.0018526"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tTseha ST. Role of Adenoviruses in Cancer Therapy. Front Oncol. 2022 Jun 9;12:772659.","DOI":"10.3389\/fonc.2022.772659"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tSercan O, Stoycheva D, H\u00e4mmerling GJ, Arnold B, Sch\u00fcler T. IFN-gamma receptor signaling regulates memory CD8+ T cell differentiation. J Immunol. 2010 Mar 15;184(6):2855\u201362.","DOI":"10.4049\/jimmunol.0902708"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tJorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res. 2020 Sep 29;8:49.","DOI":"10.1186\/s40364-020-00228-x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tWilliams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol. 2007;25:171\u201392.","DOI":"10.1146\/annurev.immunol.25.022106.141548"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tKim C, Fang F, Weyand CM, Goronzy JJ. The life cycle of a T cell after vaccination - where does immune ageing strike? Clin Exp Immunol. 2017 Jan;187(1):71\u201381.","DOI":"10.1111\/cei.12829"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tMallet M, Boulos RE, Alcazer V, Bonaventura P, Estornes Y, Chuvin N, et al. Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy. Eur J Cancer. 2022 Aug;171:96\u2013105.","DOI":"10.1016\/j.ejca.2022.05.008"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tMassarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jan 1;5(1):67\u201373.","DOI":"10.1001\/jamaoncol.2018.4051"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tKos FJ, Frankel P, Cristea M, Eng M, Tinsley R, Dempsey S, et al. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer. Cancer Res Commun. 2023 Dec 20;3(12):2585\u201395.","DOI":"10.1158\/2767-9764.CRC-23-0394"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tYoun JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 2020 Dec;21(12):1653\u201360.","DOI":"10.1016\/S1470-2045(20)30486-1"}],"container-title":["Journal of Cancer Immunology"],"original-title":[],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:30:39Z","timestamp":1776666639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.scientificarchives.com\/article\/predicting-durable-anti-tumor-immune-responses-after-cancer-vaccines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,20]]}},"URL":"https:\/\/doi.org\/10.33696\/cancerimmunol.8.119","relation":{},"ISSN":["2689-968X"],"issn-type":[{"value":"2689-968X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}